IN16 RESURRECTING PARP INHIBITION

Abstract

s / The Breast 24 S3 (2015) S21–S75 S27 Locally Advanced Or Metastatic Breast Cancer Previously Treated With Anthracyclines And Taxanes. 2012 CTRC-AACR San Antonio Breast Cancer Symposium. [3] Tutt A et al. TNT: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer. 2014 CTRC-AACR San Antonio Breast Cancer Symposium. Abstract S3-01 [4] O’Shaughnessy J et al. A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J Clin Oncol 28:15s, 2010 (suppl; abstr 1005). [5] Carey LA et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol. 2012 Jul 20;30(21):2615-23 [6] Baselga J et al. Cetuximab + Cisplatin in Estrogen Receptor-Negative, Progesterone Receptor-Negative, HER2-Negative (Triple-Negative) Metastatic Breast Cancer: Results of the Randomized Phase II BALI1 Trial. Cancer Research: December 15, 2010; Volume 70, Issue 24, Supplement 2. [7] Gelmon KA et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011 Sep;12(9):852-61 [8] Emens L et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC). AACR Annual Meeting; Philadelphia, PA. Abstract 6317